Sullivan & Cromwell LLP Logo
  • Home
  • Lawyers
  • Practices
  • Insights
  • About
  • Careers
  • Alumni
  • Twitter icon
  • LinkedIn icon
  •  icon
  • Podcasts icon
© 2025 Sullivan & Cromwell LLP
    • Home
    • Lawyers
    • Practices
    • Insights
    • About
    • Careers
    • Alumni
    Home /  Lawyers /  Keith A. Pagnani

    Keith A. Pagnani

    Partner

    Keith A. Pagnani Headshot Photo Portrait backdrop

    New York

    +1-212-558-4000

    |

    pagnanik@sullcrom.com

    Email vCard

    Keith Pagnani is a partner in Sullivan & Cromwell’s Mergers & Acquisitions Group and Co-Head of the Firm’s Healthcare and Life Sciences Group. Keith is actively involved in S&C’s corporate practice and has broad experience representing buyers, sellers, special committees and financial advisers on a wide range of domestic and cross-border transactions. He is a recognized leader in the healthcare and pharmaceuticals industry, and has played a prominent role in the sector’s most transformative transactions over the last 30 years.

    Keith serves as a member of the planning committee at Tulane University Law School’s Annual Corporate Law Institute and is Chair of the Board of P.O.T.S. (Part of the Solution), a nonprofit multi-service organization in the Bronx. He also regularly moderates and speaks on panels related to M&A, governance, trends in the healthcare space and other corporate matters, including at the Practising Law Institute and AdvaMed MedTech Conference.

    Read More

    Spotlight

    Keith Pagnani and Matt Hurd Discuss S&C’s Top Ranking for 2023 Healthcare Deals with Bloomberg Law

    Read More
    • Experience
    • Rankings and Recognitions
    • News
    • Publications, Videos and Podcasts
    • Credentials
    • Related Practices
    Experience

    Experience

    Transactions in which Mr. Pagnani has been involved include representations of:

    • Alcon and its Independent Directors in the sale of Nestlé’s Alcon stake to Novartis and Novartis’ acquisition of the remaining publicly held minority interest in Alcon for $52.9 billion
    • Bessemer Trust Company, as Trustee to the Louie E. Roche and Harvey Hubbell Trusts, in its reclassification by Hubbell Incorporated to eliminate its existing two-class structure
    • Board of Directors of Andrx in its sale to Watson Pharmaceuticals
    • Booking Holdings (f/k/a The Priceline Group) in its $1.2 billion acquisition of Getaroom from Court Square Capital Partners, $2.6 billion acquisition of OpenTable and $1.8 billion acquisition of KAYAK

    • Brown Brothers Harriman in connection with Westrock Coffee Holdings’ $1.1 billion business combination with Riverview Acquisition Corp. and in its follow-on subscription for additional common stock of Westrock Coffee Company
    • CA in its $590 million repurchase of its Common Stock from Careal Holding and acquisitions of Niku, Concord Communications and Netegrity
    • Delta Air Lines in its agreement with Air France-KLM under which it acquired a 10% stake in Air France through a capital increase of $438 million
    • Eastman Kodak in the sale of more than $3 billion of assets
    • Endo International in its $2.6 billion acquisition of Auxilium Pharmaceuticals
    • H&R Block in the sale of its financial advisory business to Ameriprise Financial
    • Harris Corporation in its $35 billion merger of equals with L3 Technologies to form L3Harris Technologies and $4.6 billion acquisition of Exelis
    • IMS Health in its sale of Erisco to the TriZetto Group and the subsequent sale of its TriZetto interest
    • ING in the sale of its U.S. investment banking business to ABN Amro
    • Kidde-Fenwal in the sale of substantially all of its assets and certain contributed assets of Carrier Group to an affiliate of Pacific Avenue Capital Partners
    • L3Harris Technologies in the $800 million sale of its Commercial Aviation Solutions business to TJC, its approximately $1.96 billion acquisition of Viasat’s Tactical Data Links product line and the $1.05 billion sale of its Military Training business to CAE
    • Lazard in its conversion from a publicly traded partnership to a U.S. C-Corporation under Delaware Law and changing its name from Lazard Ltd to Lazard, Inc.
    • Linde on its delisting from the Frankfurt Stock Exchange by way of an Irish scheme of arrangement and a subsequent inter-company merger
    • Pharmacia in its $60 billion merger with Pfizer
    • Praxair in its $80 billion merger of equals with Linde AG
    • Rabobank in its acquisition of Mid-State Bancshares
    • Special Committee of Solera Holdings in its $6.5 billion acquisition by Vista Equity Partners
    • Stryker in its $2.8 billion acquisition of Sage Products from Madison Dearborn Partners and acquisition of Stanmore Implants from SIW Holdings
    • Special Committee of the Board of Directors of Teck Resources in the proposed spin-off of Teck’s steelmaking coal business, and the six-year sunset for the multiple voting rights attached to the Class A common shares of Teck
    • UnitedHealth Group in Optum’s $3.7 billion pending acquisition of Amedisys, $6 billion merger with LHC Group, $13.8 billion acquisition of Change Healthcare, $4.3 billion acquisition of DaVita Medical Group and $12.8 billion combination with Catamaran; and its equity purchase agreement and related agreements relating to the sale of ClaimsXten to TPG Capital for $2.2 billion, tender offer for a 57% percent ownership in Empresas Banmédica and acquisitions of Sierra Health Services, Arnett HealthSystem and John Deere Healthcare
    • Special Committee of Vertrue in its acquisition by One Equity Partners

    Keith has represented Bank of America, Barclays Capital, Brown Brothers Harriman & Co., Centerview Partners, Citigroup, Goldman Sachs & Co., Greenhill & Co, Lazard Freres & Co., JPMorgan Chase & Co., Morgan Stanley, Oppenheimer & Co. and other investment banks in their capacity as financial adviser to the seller or buyer in connection with numerous transactions. Selected representations include advising the financial adviser in connection with the following M&A transactions:

    • AmerisourceBergen’s $2.5 billion acquisition of MWI Veterinary Supply
    • Board of Directors of Beacon in its $11 billion pending acquisition by QXO
    • The Beneficient Company Group’s $3.5 billion merger with Avalon Acquisition
    • Brookfield Property Partners’ (“BPY”) special committee in connection with Brookfield Asset Management’s $6.5 billion acquisition of BPY
    • Coca-Cola Enterprises’ merger of Coca-Cola Iberian Partners and Coca-Cola Erfrischungsgetränke to form Coca-Cola European Partners
    • Fresenius’ acquisition of APP Pharmaceuticals
    • General Motors’ spin-off of Hughes Defense business
    • Patterson Companies’ $1.1 billion acquisition of Animal Health International
    • Mallinckrodt in its $6.7 billion pending combination with Endo
    • PeopleSoft’s defense against and ultimate sale to Oracle
    • St. Jude Medical’s $3.3 billion acquisition of Thoratec
    • Starwood Hotels’ $12 billion acquisition by Marriott International
    • Taubman Centers’ defense against Simon Property Group’s hostile offer
    Read More
    Rankings and Recognitions

    Rankings and Recognitions

    • Chambers USA – Corporate/M&A
    • The American Lawyer “Dealmaker of the Year” – Alcon, Inc.’s Independent Directors Committee in Alcon’s $52.9 billion acquisition by Novartis AG
    • The American Lawyer “Dealmaker of the Week” – UnitedHealth’s subsidiary OptumRx’s $12.8 billion combination with Catamaran Corporation
    • The National Law Journal “Healthcare Trailblazer”
    • The Lawdragon 500: Leading Lawyers in America and Leading Dealmakers in America
    • The Lawdragon 3000: Leading Lawyers in America
    • New York Super Lawyers
    • The M&A Atlas Awards “Global M&A Lawyer of the Year”
    • Crain’s New York Business – One of 50 “Notable Nonprofit Board Leaders”
    Read More
    News

    News

    • S&C Advises Kidde-Fenwal on PFAS Bankruptcy Sale

      April 18, 2024
    • Keith Pagnani and Matt Hurd Discuss S&C’s Top Ranking for 2023 Healthcare Deals with Bloomberg Law

      December 28, 2023
    • S&C Advises Linde in Intercompany Reorganization

      March 9, 2023
    • Keith Pagnani Discusses Medtech M&A Trends on ‘Capital Forum’

      October 21, 2022
    • S&C’s Global M&A Financial Advisory Practice Continued Strong Performance in 2021

      January 31, 2022
    • S&C Advises Booking Holdings in $1.2 Billion Acquisition of Getaroom

      November 18, 2021
    Read More
    Read More
    Publications, Videos and Podcasts

    Publications, Videos and Podcasts

    • Industry and Regulatory Trends for Health Insurers

      Podcasts April 1, 2021
    • The Impact of the CARES Act on Healthcare M&A

      Podcasts June 22, 2020
    Read More
    Credentials

    Credentials

    Education

    • The Catholic University of America Columbus School of Law, J.D., 1989
    • Dickinson College, B.A., 1986

    Bar Admissions

    • Connecticut
    • New York
    Read More
    Related Practices

    Related Practices

    • General Practice
    • Artificial Intelligence
    • Corporate Governance
    • Financial Services
    • Healthcare & Life Sciences
    • Intellectual Property & Technology Transactions
    • Latin America
    • M&A Financial Advisory and Valuation
    • Mergers & Acquisitions
    • Private Equity
    • Technology
    Sullivan & Cromwell LLP Logo

    Sending an e-mail through this web site does not create an attorney-client relationship. You should not send us any information through this web site that you would want treated confidentially.

    Accept
    Sullivan & Cromwell LLP Logo
    • Twitter icon
    • LinkedIn icon
    • RSS Feed icon
    • Podcasts icon
    • Home
    • Contact Us
    • Information Policy Relating to Cookies
    • Privacy Policy
    • California Privacy Policy
    • Website Notice
    • Attorney Advertising Notice
    © 2025 Sullivan & Cromwell LLP